CD200 and B-cell chronic lymphocytic leukemia: Its distinctive expression was subsequently studied by a number of different groups, confirming that high expression of CD200 was an independent prognostic factor and predicting reduced overall survival in a number of hematological malignancies, including multiple myeloma, acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL) [7–9].